Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference New clinical data for bizaxofusp, used for the treatment of unresectable recurrent...
MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and...
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines...
NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses Up to 80 patients with...
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)...
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...
Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+ 1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics...
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...
NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/2...
TORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing...